Amgen Inc.

Company Snapshot

Founded: 1980
Entity Type: Public
Employees: 28,000
Region: U.S.
Revenue: $33,424.0 Millions
Revenue Year: 2024
Segment: Therapeutic areas
Headquarter: California, U.S.
Key Geographics: U.S., Rest of the World
Corporate Address: One Amgen Center Drive, Thousand Oaks, California - 91320-1799 U.S. Tel. +1-805-447-1000 www.amgen.com

Company Overview

Amgen discovers, develops, manufactures, and distributes innovative human therapeutics. The company offers therapeutics for diseases like cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen focuses on developing novel products based on recombinant DNA and molecular biology advances. It has a presence in over 100 countries worldwide.

The company has the most significant sales and marketing network in the U.S. and Europe. However, Amgen is expanding its commercial operations in Latin America, Japan, China, and the Middle East. In March 2022, the company introduced a new manufacturing plant in North Carolina, U.S., to increase its manufacturing network capacity. Amgen operates in one business segment: human therapeutics.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Amgen Inc. In Reports

Global Oncology Biosimilars Market

According to BCC Research detailed report on oncology biosimilars market analysis was for the base year 2024, with projections for 2025 to 2030.

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

According to BCC Research detailed report on Genetic Modification Therapies Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration

According to BCC Research detailed report on advanced drug delivery systems market estimates, data will be provided for 2024 because of the base year, with forecasts for 2025 and forecast value for 2030.

Company's Business Segments

  • Product sales : Prolia, ENBREL, Otezla, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA and Other products
  • Other revenues : Royalty income and corporate partner revenues.

Applications/End User Industries

  • Production of White Blood Cells
  • Chemotherapy
  • Reducing the Risk of Infectio
  • Treatment for Autoimmune Diseases
  • Rheumatoid Arthritis
  • Psoriasis
  • Stimulate Red Blood Cell Production
  • Anemia
  • Chronic Kidney Disease
  • Novel Therapies
  • Academic Institutions
  • CGD Specialist
  • Aimovig
  • Migraine
  • Nephrology
  • Oncology
  • Melanoma
  • Drug Development
AI Sentiment